TD Private Client Wealth’s Procept Biorobotics PRCT Stock Holding History

TD Private Client Wealth’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.51K	Buy	+83	New	+$1.66K	﹤0.01%	1433

Other funds holding PRCT

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Bastion Asset Management Montreal, Canada $229M AUM 5.92% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return

TD Private Client Wealth's PRCT Position: Q3 2026 in Review

TD Private Client Wealth opened a new position in Procept Biorobotics (PRCT) in Q3 2026: 83 shares worth $1.51K. The stake represents ﹤0.01% of the portfolio and ranks #1433 among its holdings.

89 funds tracked by Wall St. Rank hold PRCT as of Q3 2026.

TD Private Client Wealth held 83 shares of Procept Biorobotics worth $1.51K as of Q3 2026.
Procept Biorobotics was a new TD Private Client Wealth position in Q3 2026.
Procept Biorobotics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q3 2026, its #1433 holding.
89 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2026.

Based on TD Private Client Wealth's 13F filing for Q3 2026, filed 28 Oct 2026.